A complete application in a minute — tailored resume and cover letter, ready to send.
Nexcella, Inc. is seeking an Associate Director of Regulatory Affairs to drive regulatory strategy and execution for clinical trials under FDA/EMA/Health Canada/MHRA guidelines.
The role focuses on preparing, submitting, and maintaining regulatory documents with meticulous attention to detail and strong analytical skills. You will oversee IND filings, monitor regulatory changes, coordinate with internal teams and external partners, and support regulatory audits and inspections to ensure
The Director of Regulatory Affairs will support the regulatory strategy and execution for clinical trials conducted under FDA/EMA/Other Regulatory agencies regulations. This role is responsible for preparing, submitting, and maintaining regulatory documents and ensuring compliance with all applicable laws and guidelines. The ideal candidate will demonstrate strong attention to detail, analytical skills, and knowledge of FDA/EMA/HealthCanada/MHRA requirements for investigational products.
Nexcella, Inc. is a subsidiary of Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases. Our lead candidate is sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 with a proprietary CD3ζ, CD8 hinge and binder “digital filter” designed to filter out non‑specific activation. NXC-201 teaches the immune system to recognize and eliminate the source of the toxic light chains. NXC-201 is being evaluated in the U.S. multi-center study for relapsed/refractory AL Amyloidosis NEXICART-2 (NCT06097832), with a potentially registrational design. NXC-201 has been awarded Breakthrough Therapy Designation (BTD) and Regenerative Medicine Advanced Therapy (RMAT) by the US FDA and Orphan Drug Designation (ODD) by FDA and in the EU by the EMA. Learn more at www.nexcella.com and www.BeProactiveInAL.com.